Skip to main content

. 2022 Sep 1:1. Online ahead of print. doi: 10.1038/s41422-022-00713-y

Publisher Correction: Dalbavancin: novel candidate for COVID-19 treatment

Markus Hoffmann ^1,^2,^✉, Yeonhwa Jin ^1,², Stefan Pöhlmann ^1,^2,^✉

PMCID: PMC9436721 PMID: 36050376

Correction to: Cell Research 10.1038/s41422-020-00459-5, published online 20 January 2021

The licence information was missing from this article and should have been CC-BY.

The original article has been corrected.

Contributor Information

Markus Hoffmann, Email: mhoffmann@dpz.eu.

Stefan Pöhlmann, Email: spoehlmann@dpz.eu.

ACTIONS

RESOURCES